Randomized, Controlled, Double-Blind, Cross-Over Trial Assessing Treatment Preference for Pazopanib Versus Sunitinib in Patients With Metastatic Renal Cell Carcinoma: PISCES Study

2014438 citationsJournal Articlebronze Open Access

Authors

Bernard Escudier

Camillo Porta

Abstract

This innovative cross-over trial demonstrated a significant patient preference for pazopanib over sunitinib, with HRQoL and safety as key influencing factors.

Topics & Keywords

Renal cell carcinoma treatment Economic and Financial Impacts of Cancer Renal and related cancers

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Journal of Clinical Oncology

Volume 32, Issue 14, pp. 1412-1418

DOI: 10.1200/jco.2013.50.8267

Field-Weighted Citation Impact: 51.83